ArticleClinics (Sao Paulo, Brazil)2026
A pioneering transition program for adults with phenylketonuria - initial findings from a single-center one-year experience from Poland.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background In August 2024, at the University Hospital in Krakow, we initiated, for the first time in Poland, the transition of individuals with hyperphenylalaninemia to the adult metabolic center. We evaluated the experience and outcomes during the first year of this transition program. Methods We included 120 adults with hyperphenylalaninemia who were followed between August 1st, 2024, and July 31st, 2025, in the Outpatient Metabolic Clinic at the University Hospital in Krakow, Poland. Results The mean age of individuals was 31.77±10.80 years (range 18‒68); 69 (57.5%) were females. The majority, 101 (84.2%), were individuals with classic Phenylketonuria (PKU). Twenty (17.7%) individuals were off-diet, and a further 38 (33.6%) reported poor adherence. Participants were followed for a median of 5.6 (3.5‒7.7) months. The mean DBS Phe concentration from the 5-year period preceding the transition was 717.00±350.40 µmoL/L, with a mean percentage of results > 600 µmoL/L of 57.0 ± 41.4%. The mean Phe concentration during the follow-up period was 689.40±373.20 µmoL/L, with 55.5 ± 44.2% of Phe measurements exceeding the target value of 600 µmoL/L, revealing no significant change (p = 0.868 and 0.754, respectively). Seven (26.9%) children of transitioned individuals showed symptoms of maternal PKU. Conclusions The initially poor Phe control in the cohort studied remained unchanged after transferring to the adult center, emphasizing that maintaining a restrictive diet in adults with PKU is challenging. Alarmingly high prevalence of unplanned pregnancies and maternal PKU highlights critical reproductive health concerns in this population. A longer follow-up is needed to assess the impact of the transition on the metabolic control of Phe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.